Home > Insider Trading > Filing (0001104659-16-163804)

Filing Details

Accession Number:: 0001104659-16-163804
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-12-23 18:02:39
Reporting Period:: 2016-10-18

Filing Date:: 2016-12-23
Accepted Time:: 2016-12-23 18:02:39
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1674416	Crispr Therapeutics Ag	CRSP	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1354345	Phd J Bradley Bolzon	C/O Crispr Therapeutics, Inc., 200 Sidney Street Cambridge MA 02139		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-10-24	437,247	$0.00	676,895	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2016-10-24	3,100,477	$0.00	3,777,372	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2016-10-24	231,077	$0.00	4,008,449	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2016-10-24	95,596	$14.00	4,104,045	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2016-10-24	2,754	$0.00	2,754	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2016-10-24	19,524	$0.00	22,278	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2016-10-24	1,454	$0.00	23,732	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2016-10-24	602	$14.00	24,334	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2016-10-24	2,210,417	$0.00	2,210,417	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2016-10-24	173,167	$0.00	2,383,584	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2016-10-24	60,219	$14.00	2,443,803	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2016-10-24	66,490	$0.00	66,490	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2016-10-24	5,210	$0.00	71,700	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2016-10-24	168,224	$0.00	168,224	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2016-10-24	13,180	$0.00	181,404	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2016-10-24	4,583	$14.00	185,987	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2016-10-24	73,704	$0.00	73,704	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2016-10-24	5,774	$0.00	79,478	No	4	C	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2016-10-18	30,000	$0.00	30,000	$14.00
Common Stock	Series A-1 Preferred Shares	Disposition	2016-10-24	437,247	$0.00	437,247	$0.00
Common Stock	Series A-1 Preferred Shares	Disposition	2016-10-24	2,754	$0.00	2,754	$0.00
Common Stock	Series A-2 Preferred Shares	Disposition	2016-10-24	3,100,477	$0.00	3,100,477	$0.00
Common Stock	Series A-2 Preferred Shares	Disposition	2016-10-24	19,524	$0.00	19,524	$0.00
Common Stock	Series A-3 Preferred Shares	Disposition	2016-10-24	2,210,417	$0.00	2,210,417	$0.00
Common Stock	Series A-3 Preferred Shares	Disposition	2016-10-24	66,490	$0.00	66,490	$0.00
Common Stock	Series A-3 Preferred Shares	Disposition	2016-10-24	168,224	$0.00	168,224	$0.00
Common Stock	Series A-3 Preferred Shares	Disposition	2016-10-24	73,704	$0.00	73,704	$0.00
Common Stock	Series B Preferred Shares	Disposition	2016-10-24	231,077	$0.00	231,077	$0.00
Common Stock	Series B Preferred Shares	Disposition	2016-10-24	1,454	$0.00	1,454	$0.00
Common Stock	Series B Preferred Shares	Disposition	2016-10-24	173,167	$0.00	173,167	$0.00
Common Stock	Series B Preferred Shares	Disposition	2016-10-24	5,210	$0.00	5,210	$0.00
Common Stock	Series B Preferred Shares	Disposition	2016-10-24	13,180	$0.00	13,180	$0.00
Common Stock	Series B Preferred Shares	Disposition	2016-10-24	5,774	$0.00	5,774	$0.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
60,000	2026-10-18	No	4	A	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	684,014	Indirect	See footnote

Footnotes

Each of the Reporting Person and Thomas Woiwode are managing members of Versant Venture Management, LLC. One-half of these shares were issued to the Reporting Person and one-half of these shares were issued to Mr. Woiwode, in each case, as compensation for service on the Issuer's board of directors. Pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Woiwode are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
Each share of the Issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock, Series A-3 Preferred Stock and Series B Preferred Stock automatically converted into 1 share of the Issuer's Common Stock in its firm commitment initial public offering pursuant to the Issuer's prospectus (Form 424B4) filed with the Securities and Exchange Commission on October 19, 2016.
These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V (Canada) GP-GP, Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the shares through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein, if any.
These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
The option grant reported hereby was made to Thomas Woiwode as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person (the grant of which was previously reported by the Reporting Person) and one-half of the reported securities are held by Mr. Woiwode. Pursuant to the agreements described in footnote (1), the Reporting Person and Mr. Woiwode are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in Versant Venture Management, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
This option was granted on October 18, 2016 with respect to 30,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments beginning October 31, 2016.